产品说明书
Flecainide
 |
同义名 : | - |
| CAS号 : | 54143-55-4 | |
| 货号 : | A879202 | |
| 分子式 : | C17H20F6N2O3 | |
| 纯度 : | 95% | |
| 分子量 : | 414.34 | |
| MDL号 : | MFCD00864713 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(253.42 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias[3]. Its primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic testing is used as an endpoint[4]. Intravenous flecainide cardioversion could be a safe and effective option for emergency physicians to restore sinus rhythm in selected patients with acute AF (Atrial fibrillation) [5]. Flecainide is a well-tolerated medication, even at 12 months, with very minor adverse effects[6]. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease[7]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00578617 | Atrial Fibrillation ... 展开 >> Arrhythmia 收起 << | Not Applicable | Completed | - | United States, Alabama ... 展开 >> Universtity of Alabama Hospital Birminham, Alabama, United States, 35233 United States, California Good Samaritan Hospital Los Angeles, California, United States, 90017 United States, Illinois Loyola University Maywood, Illinois, United States, 60626 United States, Iowa Mercy Medical Center Des Moines, Iowa, United States, 50314 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Massachusetts Brigham and Womens Hospital Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55902 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pennsylvania Health Philadelphia, Pennsylvania, United States, 19104 United States, Utah Intermountain Medical Center Murray, Utah, United States, 84157 收起 << |
| NCT03737929 | Atrial Fibrillation | Not Applicable | Not yet recruiting | January 2022 | France ... 展开 >> CHU Toulouse, Hôpital Rangueil Not yet recruiting Toulouse, France, 31059 Contact: Philippe Maury, MD 05 61 32 34 56 ext +33 maury.p@chu-toulouse.fr Contact: Anne Rollin, MD rollin.a@chu-toulouse.fr Principal Investigator: Philippe Maury, MD Sub-Investigator: Anne Rollin, MD Sub-Investigator: Bertrand Marcheix, MD Sub-Investigator: Etienne Grunenwald, MD 收起 << |
| NCT00578617 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.41mL 0.48mL 0.24mL |
12.07mL 2.41mL 1.21mL |
24.13mL 4.83mL 2.41mL |
| 参考文献 |
|---|
|
[4]Falk RH, Fogel RI. Flecainide. J Cardiovasc Electrophysiol. 1994 Nov;5(11):964-81 |